Over de afgelopen jaren hebben wij bijdragen geleverd aan diverse nationale en internationale publicaties betreffende ons onderzoeksveld.

Selectie van recente publicaties


de Rooij MF, Kuil A, Kraan W, Kersten MJ, Treon SP, Pals ST, Spaargaren M. Ibrutinib and idelalisib target B cell receptor- but not CXCL12/CXCR4-controlled integrin-mediated adhesion in Waldenström macroglobulinemia. Haematologica. 2016 Mar;101(3):e111-5.[PubMed]


Thijssen R, Ter Burg J, van Bochove GG, de Rooij MF, Kuil A, Jansen MH, Kuijpers TW, Baars JW, Virone-Oddos A, Spaargaren M, Egile C, van Oers MH, Eldering E, Kersten MJ, Kater AP. The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells. Leukemia. 2016 Feb;30(2):337-45.[PubMed]



van Keimpema M, Grüneberg LJ, Mokry M, van Boxtel R, van Zelm MC, Coffer P, Pals ST, Spaargaren M. The forkhead transcription factor FOXP1 represses human plasma cell differentiation. Blood. 2015 Oct 29;126(18):2098-109.[PubMed]


de Rooij MF, Kuil A, Kater AP, Kersten MJ, Pals ST, Spaargaren M. Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy. Blood. 2015 Apr 2;125(14):2306-9.[PubMed]


Spaargaren M. Ibrutinib for AML? Check CD117 (KIT)! Lancet Haematol. 2015 May;2(5):e180-1.[PubMed]


Spaargaren M, de Rooij MF, Kater AP, Eldering E. BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future. Oncogene. 2015 May 7;34(19):2426-36.[PubMed]



Kersten MJ, Kraan W, Doorduijn J, Bromberg J, Lam K, Kluin PM, van der Holt BJ, Spaargaren M, Pals ST. Diffuse large B cell lymphomas relapsing in the CNS lack oncogenic MYD88 and CD79B mutations. Blood Cancer J. 2014 Dec 12;4:e266.[PubMed]


van Keimpema M, Grüneberg LJ, Mokry M, van Boxtel R, Koster J, Coffer PJ, Pals ST, Spaargaren M.FOXP1 directly represses transcription of proapoptotic genes and cooperates with NF-κB to promote survival of human B cells. Blood. 2014 Nov27;124(23):3431-40.[PubMed]


Kater AP, Eldering E, miR in CLL: more than mere markers of prognosis? Blood. 2014 Jul 3;124(1):2-4. doi: 10.1182/blood-2014-05-574152. No abstract available. [PubMed]


Te Raa GD, Malčiková J, Mraz M, Trbusek M, Le Garff-Tavernier M, Merle-Béral H, Greil R, Merkel O, Pospíšilová S, Lin K, Pettitt AR, Stankovic T, van Oers MH, Eldering E, Stilgenbauer S, Zenz T, Kater AP, Asessment of TP53 functionality in chronic lymphocytic leukaemia by different assays; an ERIC-wide approach European Research Initiative on CLL (ERIC). Br J Haematol. 2014 Jun 30. doi: 10.1111/bjh.13006. [Epub ahead of print] No abstract available. [PubMed]


Spaargaren M, de Rooij MF, Kater AP, Eldering E, BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future. Oncogene. 2014 Jun 23. doi: 10.1038/onc.2014.181. [Epub ahead of print] [PubMed]


Kraan W, van Keimpema M, Horlings HM, Schilder-Tol EJ, Oud ME, Noorduyn LA, Kluin PM, Kersten MJ, Spaargaren M, Pals ST. High prevalence of oncogenic MYD88 and CD79B mutations in primary testicular diffuse large B-cell lymphoma. Leukemia. 2014 Mar;28(3):719-20. doi: 10.1038/leu.2013.348. Epub 2013 Nov 20. [PubMed]


te Raa GD, Pascutti MF, García-Vallejo JJ, Reinen E, Remmerswaal EB, ten Berge IJ, van Lier RA, Eldering E, van Oers MH, Tonino SH, Kater AP. CMV-specific CD8+ T-cell function is not impaired in chronic lymphocytic leukemia. Blood. 2014 Jan 30;123(5):717-24. doi: 10.1182/blood-2013-08-518183. Epub 2013 Nov 18. [PubMed]


Kater AP, Spiering M, Liu RD, Doreen Te Raa G, Slinger E, Tonino SH, Beckers MM, Daenen S, Doorduijn JK, Lankheet NA, Luijks DM, Eldering E, van Oers MH. Dasatinib in combination with fludarabine in patients with refractory chronic lymphocytic leukemia: a multicenter phase 2 study. Leuk Res. 2014 Jan;38(1):34-41. doi: 10.1016/j.leukres.2013.10.004. Epub 2013 Oct 28. [PubMed]


Struemper H, Sale M, Patel BR, Ostergaard M, Osterborg A, Wierda WG, Hagenbeek A, Coiffier B, Jewell RC. Population Pharmacokinetics of Ofatumumab in Patients With Chronic Lymphocytic Leukemia, Follicular Lymphoma, and Rheumatoid Arthritis. J Clin Pharmacol. 2014 Jan 20. doi: 10.1002/jcph.268. [Epub ahead of print] [PubMed]


Sander B, de Jong D, Rosenwald A, Xie W, Balagué O, Calaminici M, Carreras J, Gaulard P, Gribben J, Hagenbeek A, Kersten MJ, Molina TJ, Lee A, Montes-Moreno S, Ott G, Raemaekers J, Salles G, Sehn L, Thorns C, Wahlin BE, Gascoyne RD, Weller E. The reliability of immunohistochemical analysis of the tumor microenvironment in follicular lymphoma: a validation study from the Lunenburg Lymphoma Biomarker Consortium. Haematologica. 2014 Apr;99(4):715-25. doi: 10.3324/haematol.2013.095257. Epub 2014 Feb 7. [PubMed]



Morschhauser F, Radford J, Van Hoof A, Botto B, Rohatiner AZ, Salles G, Soubeyran P, Tilly H, Bischof-Delaloye A, van Putten WL, Kylstra JW, Hagenbeek A. 90Yttrium-Ibritumomab Tiuxetan Consolidation of First Remission in Advanced-Stage Follicular Non-Hodgkin Lymphoma: Updated Results After a Median Follow-Up of 7.3 Years From the International, Randomized, Phase III First-Line Indolent Trial. J Clin Oncol. 2013 Apr 1. [Epub ahead of print] [PubMed]


Hagenbeek A. Rituximab maintenance versus radio-immunotherapy consolidation in first remission follicular non-Hodgkin lymphoma. Transfus Apher Sci. 2013 Aug;49(1):43. doi: 10.1016/j.transci.2013.05.024. Epub 2013 Aug 7. [PubMed]


Pascutti MF, Jak M, Tromp JM, Derks IA, Remmerswaal EB, Thijssen R, van Attekum MH, van Bochove GG, Luijks DM, Pals ST, van Lier RA, Kater AP, van Oers MH, Eldering E., IL-21 and CD40L signals from autologous T cells can induce antigen-independent proliferation of CLL cells Blood. 2013 Oct 24;122(17):3010-9. doi: 10.1182/blood-2012-11-467670. Epub 2013 Sep 6. [PubMed]


Kraan W, Horlings HM, van Keimpema M, Schilder-Tol EJ, Oud ME, Scheepstra C, Kluin PM, Kersten MJ, Spaargaren M, Pals ST. High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites. Blood Cancer J. 2013 Sep 6;3:e139. doi: 10.1038/bcj.2013.28. [PubMed]; PubMed Central PMCID: PMC3789201.


Lascano V, Guadagnoli M, Schot JG, Luijks DM, Guikema JE, Cameron K, Hahne M, Pals S, Slinger E, Kipps TJ, van Oers MH, Eldering E, Medema JP, Kater AP., Chronic lymphocytic leukemia disease progression is accelerated by APRIL / TACI interaction in the TCL1 transgenic mouse modelBlood. 2013 Dec 5;122(24):3960-3. doi: 10.1182/blood-2013-04-497693. Epub 2013 Oct 7. [PubMed]


Chang BY, Francesco M, De Rooij MF, Magadala P, Steggerda SM, Huang MM, Kuil A, Herman SE, Chang S, Pals ST, Wilson W, Wiestner A, Spaargaren M, Buggy JJ, Elias L. Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients. Blood. 2013 Oct 3;122(14):2412-24. doi: 10.1182/blood-2013-02-482125. Epub 2013 Aug 12. [PubMed]; PubMed Central PMCID: PMC3790509.


Kocemba KA, van Andel H, de Haan-Kramer A, Mahtouk K, Versteeg R, Kersten MJ, Spaargaren M, Pals ST. The hypoxia target adrenomedullin is aberrantly expressed in multiple myeloma and promotes angiogenesis. Leukemia. 2013 Mar 12. doi: 10.1038/leu.2013.76. [Epub ahead of print] [Pubmed]


Maas C, Tromp JM, van Laar J, Thijssen R, Elias JA, Malara A, Krippner-Heidenreich A, Silke J, van Oers MH, Eldering E,CLL cells are resistant to smac mimetics because of an inability to form a ripoptosome complex. Cell Death Dis. 2013 Aug 29;4:e782. doi: 10.1038/cddis.2013.305.[Pubmed]


Wensveen FM, Geest CR, Libregts SF, Derks IA, Ekert PG, Labi V, Villunger A, Nolte MA, Eldering E. BH3-only protein Noxa contributes to apoptotic control of stress-erythropoiesis. Apoptosis. 2013 Nov;18(11):1306-18. doi: 10.1007/s10495-013-0890-y. [PubMed] ; PubMed Central PMCID: PMC3825139.


te Raa GD, Malcikova J, Pospisilova S, Trbusek M, Mraz M, Garff-Tavernier ML, Merle-Béral H, Lin K, Pettitt AR, Merkel O, Stankovic T, van Oers MH, Eldering E, Stilgenbauer S, Zenz T, Kater AP; European Research Initiative on CLL (ERIC). Overview of available p53 function tests in relation to TP53 and ATM gene alterations and chemoresistance in chronic lymphocytic leukemia. Leuk Lymphoma. 2013 Aug;54(8):1849-53. doi: 10.3109/10428194.2013.796058. Epub 2013 Jun 24. Review. [PubMed]


de Weerdt I, Elderingh E, van Oers MH, Kater AP, The biological rationale and clinical efficacy of inhibition of signaling kinases in chronic lymphocytic leukemia. Leukemia research 2013 [article in press] []


Reijmers RM, Spaargaren M, Pals ST, Heparan sulfate proteoglycans in the control of B cell development and the pathogenesis of multiple myeloma. FEBS J. 2013 Feb 18. doi: 10.1111/febs.12180. [Epub ahead of print]  [Pubmed]


Wensveen FM, Klarenbeek PL, van Gisbergen KP, Pascutti MF, Derks IA, van Schaik BD, Ten Brinke A, de Vries N, Cekinovic D, Jonjic S, van Lier RA, Eldering E. Pro-apoptotic protein Noxa regulates memory T cell population size and protects against lethal immunopathology. J Immunol. 2013 Feb 1;190(3):1180-91. doi: 10.4049/jimmunol.1202304. Epub 2012 Dec 31. [PubMed]


Hoogeboom R, van Kessel KP, Hochstenbach F, Wormhoudt TA, Reinten RJ, Wagner K, Kater AP, Guikema JE, Bende RJ, van Noesel CJ. A mutated B cell chronic lymphocytic leukemia subset that recognizes and responds to fungi. J Exp Med. 2013 Jan 14;210(1):59-70. [PubMed]



Czuczman, M.S., L. Fayed, V. Delwail, G. Cartron, E. Jacobson, K. Kuliczkowski, B.K. Link, L. Pinter-Brown, J. Radford, A. Hellmann, E. Gallop-Evans, C. DiRenzo, N. Goldstein, I. Gupta, R.C. Jewell, T.S. Lin, S. Lisby, M. Schultz, C.A. Russel, A. Hagenbeek – Ofatumumab monotherapy in Rituximab-refractory follicular lymphoma: Results from a multicenter study – Blood 119 (2012) pp. 3698-3704 [PubMed]


De Rooij MF, Kuil A, Geest CR, Eldering E, Chang BY, Buggy JJ, Pals ST, Spaargaren M. 2012. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood 119(11):2590-4. [PubMed]


Kocemba KA, Groen RW, van Andel H, Kersten MJ, Mahtouk K, Spaargaren M, Pals ST. 2012. Transcriptional silencing of the Wnt-antagonist DKK1 by promoter methylation is associated with enhanced Wnt signaling in advanced Multiple Myeloma. PLoS One. 7(2):e30359.[PubMed]


Lokhorst HM, van der Holt B, Cornelissen JJ, Kersten MJ, van Oers M, Raymakers R, Minnema MC, Zweegman S, Janssen JJ, Zijlmans M, Bos G, Schaap N, Wittebol S, de Weerdt O, Ammerlaan R, Sonneveld P. Donor versus no donor comparison of newly diagnosed myeloma patients included in the HOVON 50 multiple myeloma study. Blood. 2012 Mar 22. [Epub ahead of print] [PubMed]


Kersten MJ, Doorduijn JK, Ghidey W, Spiering M, Steijaert M, Meulendijks I, Hagenbeek A. HOVON 110: ReBeL-studie: een gerandomiseerde fase I/II-studie naar de effectiviteit en veiligheid van behandeling met lenalidomide en rituximab, met of zonder bendamustine, bij volwassen patiënten met recidief folliculair lymfoom. Nederlands Tijdschrift voor Hematologie (2012;9:71-5)


Hagenbeek A Brentuximab vedotin bijNTvH de behandeling van het hogdkinlymfoom. Een doorbraak? Nederlands Tijdschrift voor Hematologie (2012;9:124-9) NTvH


Tonino SH, van de Berg PJ, Yong SL, Ten Berge IJ, Kersten MJ, van Lier RA, van Oers MH, Kater AP. Expansion of effector T cells associated with decreased PD-1 expression in patients with indolent B cell lymphomas and chronic lymphocytic leukemia. Leuk Lymphoma. 2012 Apr 19. [Epub ahead of print] [PubMed]


Tromp JM, Geest CR, Breij EC, Elias JA, van Laar J, Luijks DM, Kater AP, Beaumont T, van Oers MH, Eldering E. Tipping the Noxa/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia. Clin Cancer Res. 2012 Jan 15;18(2):487-98. [PubMed]


van Maldegem F, Wormhoudt TA, Mulder MM, Oud ME, Schilder-Tol E, Musler AR, Aten J, Saeed P, Kersten MJ, Pals ST, van Noesel CJ, Bende RJ. Chlamydia psittaci-negative ocular adnexal marginal zone B-cell lymphomas have biased V(H)4-34 immunoglobulin gene expression and proliferate in a distinct inflammatory environment. Leukemia. 2012 Feb 3. doi: 10.1038/leu.2012.28. [Epub ahead of print] [PubMed]


Kersten MJ, Doorduijn JK, Ghidey W, Spiering M, Steijaert M, Meulendijks I, Hagenbeek A. HOVON 110: ReBeL-studie: een gerandomiseerde fase I/II-studie naar de effectiviteit en veiligheid van behandeling met lenalidomide en rituximab, met of zonder bendamustine, bij volwassen patiënten met recidief folliculair lymfoom. Nederlands Tijdschrift voor Hematologie (2012;9:71-5) NTvH


Hagenbeek A Brentuximab vedotin bij de behandeling van het hogdkinlymfoom. Een doorbraak? Nederlands Tijdschrift voor Hematologie (2012;9:124-9) NTvH


van Oers MHJ, CD20 antibodies: type II to tango?. BLOOD 2012;119 (22):5061-5063 [PubMed]


Wensveen FM, Derks IA, van Gisbergen KP, de Bruin AM, Meijers JC, Yigittop H, Nolte MA, Eldering E, van Lier RA. BH3-only protein Noxa regulates apoptosis in activated B cells and controls high-affinity antibody formation. Blood. 2012 Feb 9;119(6):1440-9 [PubMed]



Groen RW, de Rooij MF, Kocemba KA, Reijmers RM, de Haan-Kramer A, Overdijk MB, Aalders L, Rozemuller H, Martens AC, Bergsagel PL, Kersten MJ, Pals ST, Spaargaren M. 2011. N-cadherin-mediated adhesion of multiple myeloma cells inhibits osteoblast differentiation. Haematologica. 96 (11):1653-61. [PubMed]


Jak M, van Bochove GG, Reits EA, Kallemeijn WW, Tromp JM, Umana P, Klein C, van Lier RA, van Oers MH, Eldering E. CD40 stimulation sensitizes CLL cells to lysosomal cell death induction by type II anti-CD20 mAb GA101. Blood. 2011 Nov 10;118(19):5178-88. [PubMed]


Jak M, van Bochove GG, van Lier RA, Eldering E, van Oers MH. CD40 stimulation sensitizes CLL cells to rituximab-induced cell death. Leukemia. 2011 Jun;25(6):968-78 [PubMed]


Kersten MJ. Radioimmunotherapy in follicular lymphoma: some like it hot….Transfus Apher Sci. 2011 Apr;44(2):173-8. [PubMed]


Persoon S, Kersten MJ, Chinapaw MJ, Buffart LM, Burghout H, Schep G, Brug J, Nollet Design of the EXercise Intervention after Stem cell Transplantation (EXIST) study: a randomized controlled trial to evaluate the effectiveness and cost-effectiveness of an individualized high intensity physical exercise program on fitness and fatigue in patients with multiple myeloma or (non-) Hodgkin's lymphoma treated with high dose chemotherapy and autologous stem cell transplantation.F. BMC Cancer. 2010 Dec 6;10:671. [PubMed]


Kneppers E, van der Holt B, Kersten MJ, Zweegman S, Meijer E, Huls G, Cornelissen JJ, Janssen JJ, Huisman C, Cornelisse PB, Bruijnen CP, Emmelot M, Sonneveld P, Lokhorst HM, Mutis T, Minnema MC. Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial Blood. 2011 Sep 1;118(9):2413-9. [PubMed]


Kwee TC, Akkerman EM, Fijnheer R, Kersten MJ, Zsíros J, Ludwig I, Bierings MB, Vermoolen MA, van Leeuwen MS, Stoker J, Nievelstein RA. MRI for staging lymphoma: whole-body or less? J Magn Reson Imaging. 2011 May;33(5):1144-50. doi: 10.1002/jmri.22549. [PubMed]


Reijmers RM, Groen RW, Kuil A, Weijer K, Kimberley FC, Medema JP, van Kuppevelt TH, Li JP, Spaargaren M, Pals ST. 2011. Disruption of heparan sulfate proteoglycan conformation perturbs B cell maturation and APRIL-mediated plasma cell survival. Blood. 117(23):6162-71. [PubMed]


Reijmers RM, Groen RW, Rozemuller H, Kuil A, de Haan-Kramer A, Csikós T, Martens AC, Spaargaren M, Pals ST. 2010. Targeting EXT1 reveals a crucial role for heparan sulfate in the growth of multiple myeloma. Blood 115:601-4. [PubMed]


Salles, G., J.F. Seymour, F. Offner, A. Lopez-Guillermo, D. Belada, L. Xerri, P. Feugier, R. Bouabdallah, J.V. Catalano, P. Brice, D. Caballero, C. Haioun, L. Moller Pedersen, A. Delmer, D. Simpson, S. Leppa, P. Soubeyran, A. Hagenbeek, O. Casasnovas, T. Intragumtornchai, C. Ferme, M. Gomes Da Silva, C. Sebban, T.A. Lister, J. Estell, G. Milone, A. Sonet, M. Mendila, B. Coiffier, H. - Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to Rituximab plus chemotherapy (PRIMA): a phase III, randomized, controlled trial – Lancet 377 (2011) pp,. 42-51. [PubMed]


Spaargaren M. 2011. Lymphoma spread? Target CD47-SIRPa! Blood 118(18):4762-4. [PubMed]


van Oers MH, Kersten MJ. Treatment strategies in advanced stage follicular lymphoma Best Pract Res Clin Haematol. 2011 Jun;24(2):187-201. [PubMed]


Younes, A., A. Hagenbeek, B. Coiffier - Optimizing the lymphoma response criteria in the era of targeted therapy – Lancet Oncology 12 (2011) pp. 616-617. [PubMed]



Mahtouk K, Tjin EP, Spaargaren M, Pals ST. 2010. The HGF/MET pathway as target for the treatment of multiple myeloma and B-cell lymphomas. Biochim Biophys Acta 1806:208-19. [PubMed]


Meerten, T. van, A. Hagenbeek – CD20 targeted therapy: The next generation of antibodies – Seminars in Hematology 47 (2010) pp. 199-210. [PubMed]


Tromp JM, Tonino SH, Elias JA, Jaspers A, Luijks DM, Kater AP, van Lier RA, van Oers MH, Eldering E. Dichotomy in NF-kappaB signaling and chemoresistance in immunoglobulin variable heavy-chain-mutated versus unmutated CLL cells upon CD40/TLR9 triggering. Oncogene. 2010 Sep 9;29(36):5071-82. [PubMed]


van Oers MHJ, Tönnissen E, van Glabbeke M, Giurgea L, Jansen JH, Klasa R, Marcus RE, Wolf M, Kimby E, Vranovsky A, Holte H, Hagenbeek A, van der Reijden BA, BCL-2/IgH Polymerase Chain Reaction Status at the End of Induction Treatment Is Not Predictive for Progression-Free Survival in Relapsed/Resistant Follicular Lymphoma: Results of a Prospective Randomized EORTC 20981 Phase III Intergroup Study. J CLIN ONCOL 2010;28 (13):2246-2252. [PubMed]



Hagenbeek, A. - Maintenance or eradication of residual disease in indolent lymphoma? Where do we stand? (Editorial) – Journal of Clinical Oncology 27 (2009) pp. 1540-1542. [PubMed]


Mous R, Jaspers A, Luijks DM, Mellink CH, van Oers MH, Kater AP, Eldering E. Detection of p53 dysfunction in chronic lymphocytic leukaemia cells through multiplex quantification of p53 target gene induction. Leukemia. 2009 Jul;23(7):1352-5. [PubMed]



De Gorter, D.J., R.M. Reijmers, E.A. Beuling, H.P.H. Naber, A. Kuil, M.J. Kersten, S.T. Pals, and M. Spaargaren. 2008. The small GTPase Ral mediates SDF-1-induced migration of B cells and multiple myeloma cells. Blood 111:3364-3372. [PubMed]


Hagenbeek, A., O. Gadeberg, P. Johnson, L.M. Pedersen, J. Walewski, A. Helmann, B.K. Link, T. Robak, M. Wojtukiewicz, M. Pfreundschuh, M. Kneba, A. Engert, P. Sonneveld, M.F. Flensburg, J. Petersen, N. Losic, J.A. Radford – First clinical use of Ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: Results of a phase I/II trial – Blood 111 (2008) pp. 5486-5495 [Pubmed]


Morschhauser F, Radford J, van Hoof A, Vitolo U, Soubeyran P, Tilly H, Huijgens PC, Kolstad A, d'Amore F, Diaz MG, Petrini M, Sebban C, Zinzani PL, van Oers MHJ, van Putten W, Bischof-Delaloye A, Rohatiner A, Salles G, Kuhlmann J, Hagenbeek A, Phase III Trial of Consolidation Therapy With Yttrium-90-Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma. J CLIN ONCOL 2008;26 (32):5156-5164. [PubMed]



De Gorter, D.J., A. Vos, S.T. Pals, and M. Spaargaren. 2007. The B cell antigen receptor controls AP-1 and NFAT activity through Ras-mediated activation of Ral. J Immunol 178:1405-1414. [PubMed]

De Gorter, D.J., E.A. Beuling, R. Kersseboom, S. Middendorp, J.M. van Gils, R.W. Hendriks, S.T. Pals, and M. Spaargaren. 2007. Bruton’s tyrosine kinase and Phospholipase Cg2 mediate chemokine-controlled B cell migration and homing. Immunity 26:93-104. [PubMed]


Kater AP, van Oers MHJ, Kipps TJ, Cellular immune therapy for chronic lymphocytic leukemia. BLOOD 2007;110 (8):2811-2818. [PubMed]


Pals, S.T., D.J. de Gorter, and M. Spaargaren. 2007. Lymphoma dissemination: the other face of lymphocyte homing. Blood 110: 3102-3111. [PubMed]


Smit LA, Hallaert DYH, Spijker R, de Goeij B, Jaspers A, Kater AP, van Oers MHJ, van Noesel CJM, Eldering E, Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity. BLOOD 2007;109 (4):1660-1668. [PubMed]

Meer publicaties